Compare ResMed Inc. (RMD) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Wendys Co — how do they compare? ResMed Inc. trades at $219.5 (market cap $31.89B), while Wendys Co trades at $7.53 (market cap $1.45B). The key difference: ResMed Inc. is far larger — about 22× Wendys Co's market cap, and Wendys Co pays the higher dividend (3.68%). Which is the better fit depends on your goals.
| RMD | WEN | |
|---|---|---|
Market Cap | $31.89B | $1.45B |
Sector | Health | Consumer Cyclical |
52-Week High | $283.28 | $9.89 |
52-Week Low | $182.82 | $6.17 |
Enterprise Value | $31.24B | $5.18B |
Dividend Yield | 1.19% | 3.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $221.05, down 3.2% amid a bearish technical signal, though it holds above key support at $218. The company reported strong Q4 2026 results with EPS of $2.95 beating estimates, and revenue grew 9% to a record $1.5 billion. However, weaker fiscal 2027 revenue guidance has pressured the stock. Fundamentals remain solid with a 26.94% net income margin and robust cash flow from operations of $1.75 billion in 2025.
The outlook is mixed; strong profitability and consistent earnings beats support upside toward the $235.70 consensus price target, but near-term sentiment is cautious due to the soft sales forecast and ongoing legal investigations. Key risks include competitive pressures and execution on guidance. Institutional buying by firms like HSBC and Canada Pension Plan provides confidence in long-term value.
Wendy's stock (WEN) trades at $7.61, down 5.23% over 24 hours, reflecting recent volatility after takeover speculation faded. The stock shows a bearish technical trend with key support at $7 and resistance at $8. Fundamentally, the company has beaten EPS estimates for three consecutive quarters but faces declining net income margins, from 7.58% in 2025 to 5.72% projected for 2026. Recent news highlights CEO Bob Wright's turnaround efforts, including a new marketing chief appointment to address quality and traffic declines.
The outlook is mixed: valuation ratios like P/E of 11.54 and P/S of 0.66 appear attractive relative to peers, but execution risks persist amid competitive pressures. Analyst consensus is cautious with 64.71% hold ratings, though the $8.13 price target implies modest upside. Key risks include sustained traffic declines and high debt levels, with debt-to-asset ratio rising to 55.68% in 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
